Brooklyn Immunotherapeuti Ownership

BTX
 Stock
  

USD 0.54  0.02  3.85%   

Some institutional investors establish a significant position in stocks such as Brooklyn Immunotherapeuti in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Brooklyn Immunotherapeuti, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Continue to Trending Equities.
  
Refresh
Preferred Dividends Income Statement Impact is likely to drop to about 14.3 K in 2022. Weighted Average Shares is likely to rise to about 46.7 M in 2022. Weighted Average Shares Diluted is likely to rise to about 46.7 M in 2022.
Brooklyn Immunotherapeuti holds a total of fifty-two million fourty thousand outstanding shares. Brooklyn Immunotherapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Brooklyn Stock Ownership Analysis

About 42.0% of the company shares are held by company insiders. The book value of Brooklyn Immunotherapeuti was currently reported as 0.25. The company recorded a loss per share of 0.45. Brooklyn Immunotherapeuti next dividend is scheduled to be issued on the 29th of November 1970. The entity had 3:1 split on the 26th of March 2021. Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York. Brooklyn Immunotherapeuti operates under Biotechnology classification in the United States and is traded on NYSEMKT Exchange. It employs 10 people. For more info on Brooklyn Immunotherapeutics please contact Michael West at 212 582 1199 or go to https://www.brooklynitx.com.
Besides selling stocks to institutional investors, Brooklyn Immunotherapeuti also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Brooklyn Immunotherapeuti's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Brooklyn Immunotherapeuti's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Brooklyn Immunotherapeuti Quarterly Share Based Compensation

1.18 Million

Share
About 42.0% of Brooklyn Immunotherapeutics are currently held by insiders. Unlike Brooklyn Immunotherapeuti's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Brooklyn Immunotherapeuti's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%.

Brooklyn Immunotherapeuti SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Brooklyn Immunotherapeuti prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Brooklyn Immunotherapeuti investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Brooklyn Immunotherapeuti specific information freely available to individual and institutional investors to make a timely investment decision.
17th of June 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View
7th of June 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
17th of May 2022
Other Events
View
16th of March 2022
Unclassified Corporate Event
View

Brooklyn Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Brooklyn Immunotherapeuti is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Brooklyn Immunotherapeutics backward and forwards among themselves. Brooklyn Immunotherapeuti's institutional investor refers to the entity that pools money to purchase Brooklyn Immunotherapeuti's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Armistice Capital LlcCommon Shares5.5 M11.3 M
Blackrock IncCommon Shares2.4 M4.9 M
Cypress Point Wealth Management LlcCommon Shares1.9 M3.9 M
Naviter Wealth LlcCommon Shares1.6 M3.2 M
Vanguard Group IncCommon Shares1.3 M2.6 M
Inverness Counsel LlcCommon Shares1.2 M2.5 M
Jpmorgan Chase CoCommon Shares822.2 K1.7 M
Citadel Advisors LlcCall Options108.7 K223 K
Note, although Brooklyn Immunotherapeuti's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Brooklyn Immunotherapeuti Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Brooklyn Immunotherapeuti insiders, such as employees or executives, is commonly permitted as long as it does not rely on Brooklyn Immunotherapeuti's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Brooklyn Immunotherapeuti insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Damour Kevin 3 days ago via Macroaxis 
Exercise or conversion by Damour Kevin of 17573 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Gurrola Sandra M over a week ago via Macroaxis 
Exercise or conversion by Gurrola Sandra M of 8750 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Gurrola Sandra M over a week ago via Macroaxis 
Payment of 3586 shares by Gurrola Sandra M of Brooklyn Immunotherapeuti subject to Rule 16b-3
Singer Nicholas Jason over three weeks ago via Macroaxis 
Brooklyn Immunotherapeuti exotic insider transaction detected
Jackson Andrew C over three weeks ago via Macroaxis 
Acquisition by Jackson Andrew C of 664800 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Angel Matthew over a month ago via Macroaxis 
Brooklyn Immunotherapeuti exotic insider transaction detected
Sidhu Roger over three months ago via Macroaxis 
Acquisition by Sidhu Roger of 142100 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Sidhu Roger over three months ago via Macroaxis 
Acquisition by Sidhu Roger of 142100 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Sidhu Roger over three months ago via Macroaxis 
Acquisition by Sidhu Roger of 142100 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Greenwood Luba over six months ago via Macroaxis 
Acquisition by Greenwood Luba of 67000 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Langer Dennis over six months ago via Macroaxis 
Acquisition by Langer Dennis of 67000 shares of Brooklyn Immunotherapeuti subject to Rule 16b-3
Denny George P Iii over six months ago via Macroaxis 
Brooklyn Immunotherapeuti exotic insider transaction detected

Brooklyn Immunotherapeuti Investors Sentiment

The influence of Brooklyn Immunotherapeuti's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Brooklyn. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Brooklyn Immunotherapeuti Implied Volatility

    
  265.78  
Brooklyn Immunotherapeuti's implied volatility exposes the market's sentiment of Brooklyn Immunotherapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Brooklyn Immunotherapeuti's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Brooklyn Immunotherapeuti stock will not fluctuate a lot when Brooklyn Immunotherapeuti's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Brooklyn Immunotherapeuti in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Brooklyn Immunotherapeuti's short interest history, or implied volatility extrapolated from Brooklyn Immunotherapeuti options trading.

Current Sentiment - BTX

Brooklyn Immunotherapeuti Investor Sentiment

Greater number of Macroaxis users are currently bullish on Brooklyn Immunotherapeutics. What is your opinion about investing in Brooklyn Immunotherapeutics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with Brooklyn Immunotherapeuti

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Brooklyn Immunotherapeuti position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brooklyn Immunotherapeuti will appreciate offsetting losses from the drop in the long position's value.

Brooklyn Immunotherapeuti Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Brooklyn Immunotherapeuti could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Brooklyn Immunotherapeuti when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Brooklyn Immunotherapeuti - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Brooklyn Immunotherapeutics to buy it.
The correlation of Brooklyn Immunotherapeuti is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Brooklyn Immunotherapeuti moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Brooklyn Immunotherapeuti moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Brooklyn Immunotherapeuti can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
29.7 M
Return On Assets
-0.74
Return On Equity
-156.16
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.